Join Growin Stock Community!

Inspiremd, inc.NSPR.US Overview

US StockHealthcare
(No presentation for NSPR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NSPR AI Insights

NSPR Overall Performance

NSPR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NSPR Recent Performance

1.40%

Inspiremd, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NSPR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NSPR Key Information

NSPR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NSPR Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Price of NSPR

NSPR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NSPR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.09
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.70
PB Ratio
1.21
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
24.91%
Net Margin
-593.89%
Revenue Growth (YoY)
14.04%
Profit Growth (YoY)
25.68%
3-Year Revenue Growth
20.81%
3-Year Profit Growth
33.15%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.09
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
9.70
PB Ratio
1.21
Price-to-FCF
-
Gross Margin
24.91%
Net Margin
-593.89%
Revenue Growth (YoY)
14.04%
Profit Growth (YoY)
25.68%
3-Year Revenue Growth
20.81%
3-Year Profit Growth
33.15%
  • When is NSPR's latest earnings report released?

    The most recent financial report for Inspiremd, inc. (NSPR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NSPR's short-term business performance and financial health. For the latest updates on NSPR's earnings releases, visit this page regularly.

  • What is the operating profit of NSPR?

    According to the latest financial report, Inspiremd, inc. (NSPR) reported an Operating Profit of -13.05M with an Operating Margin of -517.28% this period, representing a decline of 54.23% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is NSPR's revenue growth?

    In the latest financial report, Inspiremd, inc. (NSPR) announced revenue of 2.52M, with a Year-Over-Year growth rate of 39.39%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does NSPR have?

    At the end of the period, Inspiremd, inc. (NSPR) held Total Cash and Cash Equivalents of 63.4M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does NSPR go with three margins increasing?

    In the latest report, Inspiremd, inc. (NSPR) did not achieve the “three margins increasing” benchmark, with a gross margin of 34.2%%, operating margin of -517.28%%, and net margin of -503.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess NSPR's profit trajectory and future growth potential.

  • Is NSPR's EPS continuing to grow?

    According to the past four quarterly reports, Inspiremd, inc. (NSPR)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.17. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NSPR?

    Inspiremd, inc. (NSPR)'s Free Cash Flow (FCF) for the period is -8.95M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 46.17% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of NSPR?

    The latest valuation data shows Inspiremd, inc. (NSPR) has a Price-To-Earnings (PE) ratio of -1.54 and a Price/Earnings-To-Growth (PEG) ratio of 0.1. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.